

Cantor Global Healthcare Conference

September 25, 2017



MannKind Corporation®

Cautionary Statement




Today's presentation includes forward-looking statements relating to the development, commercialization and benefits of our products and investigational product candidates, including AFREZZA®, that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected herein. The words "believe," "expect," "intend," "anticipate," "plan," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult for us to predict and include, without limitation, our ability to generate significant product sales, our ability to manage our existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission. For detailed information about the risks and uncertainties that could cause actual results to differ materially from those implied by, or anticipated in, these forward looking statements, please refer to our current and periodic reports filed with the Securities and Exchange Commission from time to time, including our annual report on Form 10-K for the year ended December 31, 2016.

MannKind's Footprint is Built for Scale and Efficiency



Westlake Village, CA
*Executive Offices & Commercial
Operation*



Danbury, CT
R&D and Manufacturing
>300,000 Sq Ft

Senior Management Team with Global Biopharmaceutical and Medical Device Experience



Michael Castagna, PharmD
Chief Executive Officer

- CEO since May 2017
- Previously served as a VP and Global Commercial Lead for a portfolio of nine biosimilar drugs at Amgen
- Prior to Amgen, served as Executive Director of Bristol-Myers Squibb's Immunology franchise
- Received a BS from Philadelphia College of Pharmacy, Doctorate from MCPHS and MBA from Wharton Business School



Steven Binder
Chief Financial Officer

- CFO since July 2017
- Previously served as VP and CFO for Stryker's International Group
- Prior to Stryker, served in a series of senior leadership roles at Bristol-Myers Squibb
- Received a BA from Muhlenberg College
- Certified Public Accountant



Patrick McCauley
Chief Commercial Officer

- Chief Commercial Officer since July 2017
- Previously was in a series of senior sales and compliance leadership roles at Astellas Pharma
- Prior to Astellas, held a sales leadership role at Yamanouchi Pharma
- Received an MBA from Kellogg School of Management, JD from South Texas College of Law Houston and a BA from Notre Dame



David Thomson
Corporate VP / General Counsel

- Corporate VP since January 2002
- Prior to joining MannKind, practiced corporate and securities law at Davies Ward Phillips & Vineberg
- Previously, was post-doctoral fellow at Rockefeller University
- Received a BS, MS, and PhD from Queens University and JD from the University of Toronto



Ray Urbanski, MD, PhD
Chief Medical Officer
Until September 29, 2017

- Chief Medical Officer since August 2015
- Previously served as Chief Medical Officer at Mylan
- Prior to Mylan, served as VP and Medical Head of the Established Products Business Unit at Pfizer
- Received an MD and PhD from the University of Medicine and Dentistry of New Jersey



Courtney Barton
Chief Compliance Officer

- Chief Compliance Officer since March 2017
- Broad, global compliance and ethics roles in pharmaceutical and medical device sector with Bausch+Lomb, Allergan, KYTHERA and Anacor (Pfizer)
- Received a BS in Political Science and International Relations from Syracuse University
- Certified Compliance and Ethics Professional (CCEP)
- Certified Information Privacy Professional (CIPP US/E)



Joe Kocinsky
Chief Technology Officer

- Chief Technology Officer since October 2015; Technical Operations since 2003
- Over 30 years in pharmaceutical industry, prior at Schering-Plough
- Received an MBA from Seton Hall University.
- Holds BS in Chemical Engineering and a MS in Biomedical Engineering from New Jersey Institute of Technology



Stuart Tross
Chief People and Workplace Officer

- Chief People and Workplace Officer since December 2016
- Extensive life sciences experience; previously at Amgen, served as SVP and Chief Human Resources Officer on global basis; at Bristol-Myers Squibb as VP and Global Head of Human Resources for Mead Johnson Company
- Received a BS from Cornell University; MS and PhD in Industrial Organizational Psychology from Georgia Institute of Technology



Rose Alinaya
SVP Investor Relations


- Investor Relations since January 2016; Corporate Finance & Accounting since June 2003
- Started career at Deloitte
- Member of the American Institute of Certified Public Accountants and California Society of Certified Public Accountants
- Received a BS from California State University
- Certified Public Accountant

Potential US Insulin Treatment Market is Over 23M People and Growing Globally



Type 2 population continues to grow each year, which ultimately drives growth in the insulin-using population

Illustrative Type 2 Progression and US Patient Estimates




~70% of people in the US on insulin are not at goal despite adoption of analogue insulin and insulin pumps

Despite many new diabetes treatments coming to market in the past decade, patient success remains limited, and patients require a simple means of managing their disease

- ~70% of patients on insulin are not achieving <7% A1C (i.e., “target” A1C level)
 - In a recent survey of diabetic patients, fewer than 1 out of 3 patients felt “very successful” in various elements of managing their disease
- The need to manage mealtime glucose (PPG) increases as patients get closer to A1C target
 - As A1Cs trend closer to 7%, management of PPG (mealtime) becomes increasingly important


Insulin Patients Achieving A1C Goals⁽¹⁾



(1) Diabetes Care 2016 Mar; 39(3): e33-e35. <https://doi.org/10.2337/dc15-2229>

(2) Monnier L, et al. Diabetes Care. 2003;26:881-885

Importance of PPG Control for A1C⁽²⁾



Afrezza® (insulin human) Inhalation Powder & Inhaler




- **Afrezza® (insulin human) Inhalation Powder**

- Dry powder
- Contains human regular insulin and fumaryl diketopiperazine (FDKP) a biologically inert FDA qualified and approved excipient
- Particles ideally sized for inhalation to the deep lung (2-2.5µ)

- **Drug/Device Combination Product**

- Compact inhaler
- Pre-filled single-use cartridges (4, 8, 12 unit cartridges)
- Breath-powered delivery




We continue to transform and position MannKind as a fully integrated biopharma growth company



- **Improved near term financial position & optionality**
 - Increased cash by \$20M through The Mann Group in June 2017
 - Afrezza gross revenue grew 60% Q2 vs. Q1 2017
- **Redeployment of capital and critical resources to focus on Afrezza**
- **Continued commercial and medical affairs execution**
 - Sales force & insurance coverage expansion
 - One Drop collaboration
 - 8 clinical trials in development or ongoing
 - FDA label change
- **Product pipeline**
 - On track to file IND for treprostinil
 - Receptor Life Sciences Collaboration
- **Recapitalization process is ongoing**

Global Expansion Focus for Afrezza



>50% of the World's Population



Commercial Highlights




- First full quarter of promotion by our MannKind sales team
 - Expansion and training occurred in February and continued in Q2
- Q2 growth in both prescriptions and new writers
- Continued focus on enhanced payor coverage
- Social media enhancements
- Afrezza TV commercial launch expanding



Our commercial expansion continues to show positive momentum in Q3 and broke new cartridge record last week



Afrezza Cartridge Quantity by Week (4 week rolling avg)



Source: Symphony PHAST
CSO=Contract Sales Organization

Afrezza clinical strategy is focused on integrating technology to expose “real time” feedback loop



Starting & Staying on Afrezza

- Proper Dosing (STAT & ADD-1)
- Speed of Titration (STAT, A-ONE & ADD-1)

Integrate Digital Platforms

- One Drop (T2DM = A-ONE)
- CGM (T1DM = STAT & ADD-1)

Expand Clinical Knowledge

- Pediatric Program
- Long term study
- Closed loop (Yale)
- Generate real world data (T1DM = APEX)

Afrezza Clinical Program is Focused on Type 1 and Type 2 Diabetes



2017

2018

2019- 2024

**Pediatric PK study
(MKC-TI-155 Part 1)**



Pediatric Phase 3 (MKC-TI-155 Part 2)



Long Term Safety (MKC-TI-182)



**STAT
(Time in Range CGM)**



**ADD-1
(Afrezza Dynamic Dosing)**



**APEX
(Afrezza Patient Experience)**







**A-ONE
(Afrezza One Drop)**



**Yale
(Closed Loop)**




Submitted FDA label revisions should highlight Afrezza's unique PK:PD profile



Data presented at ADA 2016

©2017 MannKind Corporation. All rights reserved. No copying or distribution of this material may be made without written consent of MannKind Corporation.

PK/PD profiles of various new mealtime insulins will be the center of focus in upcoming launches



Study was not a head to head PK/PD and is a representative overlay based on published data

©2017 MannKind Corporation. All rights reserved. No copying or distribution of this material may be made without written consent of MannKind Corporation.

We have recently redefined our filter for development candidates for internal versus external collaborations



Development programs can be “bucketed”:

Bucket 1 - known compounds *already delivered to lung*

- Limited to no nonclinical work
- Clinical program typically comprises Phase 1 studies only (dose finding and bioequivalence to reference drug)

Bucket 2 - known compounds, non-lung delivery, *acute use*

- Nonclinical program includes short-term (14-28 day) inhalation toxicology studies
- Clinical program includes short-term efficacy studies in target patient population

Bucket 3 - known compounds, non-lung delivery, *chronic use*

- Nonclinical program includes chronic (6-9 month) inhalation toxicology studies
- Clinical program includes long-term efficacy studies in target patient population

Bucket 4 - new chemical entities (NCEs)

- Full nonclinical development program required
- Full clinical development program required

Our technology is protected by over 780 patents in force worldwide covering both utility and design



**Formulation technology,
including optimized particles
and characteristics (2034)**



**35 Patents listed in FDA's
Orange Book, Patent term
extends to 2032
Trademark Registered in
major markets**



**Methods of making/
manufacturing the formulations and
particles (2035)**



**Inhalers, cartridges,
inhalation systems, blister
package and methods of
using them (2032)**



**Inhaler testing and
support
technologies
(2030)**



**Methods of treatment
using the formulations
and inhalation systems
(2031)**



Near Term Milestones and Key Events

- Growth Trajectory Continues for Afrezza
- FDA Label Change
- Recapitalization
- International Expansion Announcements
- Receptor Life Sciences
- One Drop Collaboration
- Expansion of Payor Coverage
- Completion of STAT Trial (Afrezza+Dexcom)
- IND Filing for Treprostinil

THANK YOU

Contact:
Rose Alinaya, SVP Investor Relations,
IR@mannkindcorp.com



MannKind Corporation®